Long-term use of rosuvastatin: a critical risk benefit appraisal and comparison with other antihyperlipidemics
{{output}}
Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. In comparative trials, across dose ranges this statin reduced low-density lipop... ...
